Understanding Translation from Preclinical Models to Clinical Outcomes for Novel Linker-Payload ADC Platforms

• Attenuating payload platform toxicities through novel linker design
• Case studies for translatability of glucuronide linker ADC design with different payload classes
• Challenges of ADC toxicity assessment for linker-payloads with novel mechanisms of action

Speakers:

Jutta Deckert

Vice President, Research & Development

Iksuda Therapeutics